v3.26.1
Fair Value (Details)
6 Months Ended 12 Months Ended
Jun. 30, 2026
USD ($)
Dec. 31, 2025
USD ($)
Financial Instruments, At Carrying Value [Abstract]    
Notes due $ 0 $ 290,602,000
Credit facility $ 92,500,000 $ 102,500,000
Financial Instruments, At Fair Value [Abstract]    
Money market funds invested in U.S. government securities 100.00% 100.00%
Notes due 2026    
Financial Instruments, At Fair Value [Abstract]    
Notes due $ 0 $ 288,644,000
Net Carrying Value 0 290,602,000
Exchangeable Notes    
Financial Instruments, At Fair Value [Abstract]    
Notes due 428,373,000 0
Net Carrying Value 391,163,000 0
Term Loans    
Financial Instruments, At Fair Value [Abstract]    
Notes due 125,370,000 0
Net Carrying Value 125,370,000 0
IIP Life Science Credit Facility    
Financial Instruments, At Carrying Value [Abstract]    
Credit facility 92,500,000 75,000,000
Financial Instruments, At Fair Value [Abstract]    
Credit facility 92,500,000 75,000,000
Revolving Credit Facility    
Financial Instruments, At Carrying Value [Abstract]    
Credit facility 0 27,500,000
Financial Instruments, At Fair Value [Abstract]    
Credit facility 0 27,500,000
Revolving Facility | Revolving Credit Facility    
Financial Instruments, At Carrying Value [Abstract]    
Credit facility 0 27,500,000
Investment in IQHQ Credit Facility    
Financial Instruments, At Carrying Value [Abstract]    
Receivables 98,284,000 96,908,000
Financial Instruments, At Fair Value [Abstract]    
Receivables 98,284,000 96,908,000
Seller Financed Note    
Financial Instruments, At Carrying Value [Abstract]    
Receivables 49,000,000 0
Financial Instruments, At Fair Value [Abstract]    
Receivables 49,000,000 0
Construction Loan    
Financial Instruments, At Carrying Value [Abstract]    
Receivables 22,800,000 22,800,000
Financial Instruments, At Fair Value [Abstract]    
Receivables 30,111,000 29,997,000
Notes Receivable    
Financial Instruments, At Carrying Value [Abstract]    
Receivables 16,786,000 16,786,000
Investments as cash equivalents 0 158,000
Financial Instruments, At Fair Value [Abstract]    
Receivables 16,786,000 16,786,000
Investments as cash equivalents 0 158,000
IQHQ, Inc.    
Financial Instruments, At Fair Value [Abstract]    
Life science investments $ 177,600,000 $ 55,800,000
Expected market yield | Investment in IQHQ Credit Facility    
Financial Instruments, At Fair Value [Abstract]    
Fair value input 0.166 0.168
Expected market yield | Seller Financed Note    
Financial Instruments, At Fair Value [Abstract]    
Fair value input 0.181  
Expected market yield | Construction Loan    
Financial Instruments, At Fair Value [Abstract]    
Fair value input 0.1625  
Expected market yield | Notes Receivable    
Financial Instruments, At Fair Value [Abstract]    
Fair value input   0.1625
Expected market yield | Term Loans    
Financial Instruments, At Fair Value [Abstract]    
Weighted average discount rate 9.70%  
Weighted average expected market yield | Notes Receivable    
Financial Instruments, At Fair Value [Abstract]    
Fair value input 0.330 0.265